Q3 2024 Earnings Forecast for GSK plc Issued By Zacks Research (NYSE:GSK)

GSK plc (NYSE:GSK) – Zacks Research decreased their Q3 2024 earnings estimates for shares of GSK in a report issued on Tuesday, October 1st. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will earn $1.17 per share for the quarter, down from their prior estimate of $1.24. The consensus estimate for GSK’s current full-year earnings is $4.17 per share. Zacks Research also issued estimates for GSK’s Q4 2024 earnings at $0.76 EPS, Q3 2025 earnings at $1.36 EPS and Q3 2026 earnings at $1.56 EPS.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The firm had revenue of $9.95 billion for the quarter, compared to the consensus estimate of $9.49 billion.

Several other brokerages have also recently issued reports on GSK. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Citigroup upgraded shares of GSK to a “strong-buy” rating in a research note on Monday, June 24th. Argus raised shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group lifted their price objective on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Finally, Berenberg Bank raised GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $50.00.

GSK Stock Up 1.2 %

GSK stock opened at $38.82 on Thursday. The stock has a 50-day simple moving average of $41.57 and a 200-day simple moving average of $41.51. The company has a market capitalization of $80.45 billion, a P/E ratio of 14.07, a PEG ratio of 1.31 and a beta of 0.66. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. GSK has a fifty-two week low of $33.67 and a fifty-two week high of $45.92.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be issued a dividend of $0.3843 per share. The ex-dividend date is Friday, August 16th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a yield of 3.96%. GSK’s payout ratio is currently 54.71%.

Insiders Place Their Bets

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of the business’s stock in a transaction dated Friday, September 27th. The stock was acquired at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 10.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. JTC Employer Solutions Trustee Ltd increased its position in GSK by 71.3% during the first quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock worth $909,063,000 after buying an additional 8,800,822 shares in the last quarter. Primecap Management Co. CA boosted its stake in shares of GSK by 13.9% during the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after acquiring an additional 1,773,020 shares during the last quarter. Mondrian Investment Partners LTD increased its position in GSK by 37.8% during the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock worth $236,250,000 after purchasing an additional 1,512,442 shares in the last quarter. Fisher Asset Management LLC raised its stake in GSK by 10.6% in the 4th quarter. Fisher Asset Management LLC now owns 15,036,881 shares of the pharmaceutical company’s stock valued at $557,267,000 after purchasing an additional 1,436,488 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in GSK by 180.0% in the 1st quarter. Acadian Asset Management LLC now owns 2,219,798 shares of the pharmaceutical company’s stock valued at $95,129,000 after purchasing an additional 1,426,935 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.